| Name | Title | Contact Details |
|---|
At Mako Fire Group our main goal is helping you protect what matters most, and we take great pride in that. Our companies highly qualified technicians undergo a rigorous training surpassing what is required of them from local and state governments to ensure the highest level of satisfaction for our customers. Offering a wide array of cutting edge products including fire extinguishers, exit and emergency lights, smoke detection/alarms, etc. we are your one stop shop for fire prevention and protection. Annual services for commercial properties include Fire extinguisher maintenance, smoke alarm maintenance, emergency lighting maintenance, fire alarm maintenance, sprinkler maintenance, etc. With a corporate sized workforce and mom-and-pop style customer service, we at Mako Fire Group guarantee we will meet and exceed all your expectations.
Authentic® is a community of Fractional CMOs who help growing businesses Overcome Random Acts of Marketing® and confidently take the next right step to build revenue. Our unique approach combines Marketers + Methodology + Mindshare to build strong, strategic, sales-aligned marketing teams and programs.
DAST Consulting Services is a rapidly growing company that is part of a consortium of organizations with a vision to unlock financial resources so that every kid in America has access to a Christ-centered education. We collaborate with accredited non-public schools to help them leverage various revenue streams, including federal and state grant funding programs as well as innovative work-based learning initiatives. DAST also has an active venture studio (DAST Investments) with multiple portfolio companies, and a nonprofit (DAST Foundation) that recently launched a Classical Christian Microschool network.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.